Geetha Mylvaganam, Ph.D. is a Senior Director of Research at Abata Therapeutics and Program Lead of the Type 1 Diabetes Program. She received her Ph.D. in Immunology and Molecular Pathogenesis from Emory University in Atlanta, GA where she studied T cell dynamics in the context of SIV infection and immune correlates of viral control. She conducted her post doctorate at the Ragon Institute of MGH, MIT and Harvard in Cambridge, MA where she continued to study CD8 T cell responses in the context of HIV infection, potential regulators of CD8 T cell trafficking to secondary lymphoid sites, and how these could be leveraged for the development of HIV therapeutics. Geetha currently works at Abata therapeutics to lead their novel TCR targeting T regulatory cell therapy program for the treatment of Type 1 Diabetes.